Read by QxMD icon Read

botox stroke

Gerard E Francisco, Daniel S Bandari, Ganesh Bavikatte, Wolfgang H Jost, Aubrey Manack Adams, Joan Largent, Alberto Esquenazi
OBJECTIVE: The main aim of this study was to determine the utilization patterns and effectiveness of onabotulinumtoxinA (Botox®) for treatment of spasticity in clinical practice. DESIGN: An international, multicentre, prospective, observational study at selected sites in North America, Europe, and Asia. PATIENTS: Adult patients with newly diagnosed or established focal spasticity, including those who had previously received treatment with onabotulinum-toxin A...
August 31, 2017: Journal of Rehabilitation Medicine
Alberto Esquenazi, Stella Lee, Nathaniel Mayer, Roser Garreta, Atul Patel, Elie Elovic, Stephen Koelbel, Gerard Francisco, Iris Reuter
OBJECTIVE: The aim of the study was to report physician experience-based "real-world" treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury. DESIGN: A prospective, multicenter, international observational registry design was used. RESULTS: Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians...
December 2017: American Journal of Physical Medicine & Rehabilitation
Michael W O'Dell, Mark Villanueva, Carly Creelman, Gaurav Telhan, Jaclyn Nestor, Keith D Hentel, Douglas Ballon, Jonathan P Dyke
BACKGROUND: Although important for dosing and dilution, there are few data describing botulinum toxin (BT) movement in human muscle. OBJECTIVE: To better understand BT movement within human muscle. DESIGN: Proof-of-concept study with descriptive case series. SETTING: Outpatient academic practice. PARTICIPANTS: Five subjects with stroke who were BT naive with a mean age of 60.4 ± 14 years and time poststroke of 4...
December 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
Kyung Hee Do, Min Ho Chun, Nam-Jong Paik, Yoon Ghil Park, Shi-Uk Lee, Min-Wook Kim, Don-Kyu Kim
OBJECTIVE: To investigate a new botulinum neurotoxin type A, termed letibotulinumtoxinA(Botulax(®)) and compare its efficacy and safety for post-stroke upper limb spasticity with that of onabotulinumtoxinA(Botox(®)). DESIGN: A prospective, double-blinded, multicenter, randomized controlled clinical study. SETTING: Six university hospitals in Korea. SUBJECTS: A total of 187 stroke participants with upper limb spasticity...
September 2017: Clinical Rehabilitation
Sophie Larrazet, Romain Joste, Angélique Stefan, Anne Delaubier, André Gueyraud, Philippe Foucault, Claire Guillou, Thierry Dabbadie
OBJECTIVE: The aim of this study was to compare the analgesic effectiveness of 1 month injection after botulinum toxin in the pectoralis major muscle or subscapularis. MATERIAL/PATIENTS AND METHODS: In this prospective, comparative, randomized, multicenter trial, 21 patients with hemiplegic shoulder pain after a recent stroke (less 6 months) were screened at baseline, then postinjection (Botox(®) 150 units pectoralis major, 100 units subscaplaris) at 1, 4 and 12 weeks...
September 2016: Annals of Physical and Rehabilitation Medicine
Jeong-Gue Choi, Joon-Ho Shin, Bo-Ra Kim
OBJECTIVE: To evaluate the beneficial effect of botulinum toxin A (Botox) injection into the subscapularis muscle on intractable hemiplegic shoulder pain. METHODS: Six stroke patients with intractable hemiplegic shoulder pain were included. Botulinum toxin A was injected into the subscapularis muscle. Intractable hemiplegic shoulder pain was evaluated using an 11-point numerical rating scale. Pain-free range of motion was assessed for shoulder abduction and external rotation...
August 2016: Annals of Rehabilitation Medicine
Jörg Wissel, Vaidyanathan Ganapathy, Anthony B Ward, Jörgen Borg, Per Ertzgaard, Christoph Herrmann, Anders Haggstrom, Mohamed Sakel, Julia Ma, Rozalina Dimitrova, Antony Fulford-Smith, Patrick Gillard
CONTEXT: Patients with post-stroke spasticity (PSS) commonly experience pain in affected limbs, which may impact quality of life. OBJECTIVES: To assess onabotulinumtoxinA for pain in patients with PSS from the BOTOX(®) Economic Spasticity Trial, a multicenter, randomized, double-blind, placebo-controlled trial. METHODS: Patients with PSS (N = 273) were randomized to 22- to 34-week double-blind treatment with onabotulinumtoxinA + standard care (SC) or placebo injection + SC and were eligible to receive open-label onabotulinumtoxinA up to 52 weeks...
July 2016: Journal of Pain and Symptom Management
(no author information available yet)
No abstract text is available yet for this article.
February 2016: Nursing Older People
S E Khat'kova, D R Khasanova, L A Korenko, L N Antipova, L P Shperling, D V Popov, D V Pokhabov, E V Poznyakova
AIM: To assess the efficacy of Botulinum toxin type A (BoNT-A) injections in routine practice. MATERIAL AND METHODS: An international, post-marketing, multi-center, observational, prospective, longitudinal study included patients ≥18 years with poststroke upper-limb spasticity in whom a decision to inject BoNT-A had already been made, and who had no previous treatment with BoNT-A or BoNT-B within the last 12 weeks. The responder rate was assessed by the patient-centered goal attainment scaling (GAS)...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Maria A Chang
Botulinum toxin A (Botox A) is widely prescribed for the management of spasticity due to stroke, and many patients receive repeated injections because the paralyzing effect diminishes after 3 to 4 months. There are many studies that report local complications of Botox A at the injected site. However, little is known about non-local or systemic adverse events with repeated injections. The purpose of this research was to examine published data about adverse effects of repeated Botox A injections. MEDLINE, CINAHL, and PEDro databases were searched for articles that report adverse effects from Botox A injections for reduction of post-stroke spasticity in adults...
2015: Journal of Allied Health
Hyung Seok Nam, Yoon Ghil Park, Nam-Jong Paik, Byung-Mo Oh, Min Ho Chun, Hea-Eun Yang, Dae Hyun Kim, Youbin Yi, Han Gil Seo, Kwang Dong Kim, Min Cheol Chang, Jae Hak Ryu, Shi-Uk Lee
Botulinum toxin A is widely used in the clinics to reduce spasticity and improve upper limb function for post-stroke patients. Efficacy and safety of a new botulinum toxin type A, NABOTA (DWP450) in post-stroke upper limb spasticity was evaluated in comparison with Botox (onabotulinum toxin A). A total of 197 patients with post-stroke upper limb spasticity were included in this study and randomly assigned to NABOTA group (n=99) or Botox group (n=98). Wrist flexors with modified Ashworth Scale (MAS) grade 2 or greater, and elbow flexors, thumb flexors and finger flexors with MAS 1 or greater were injected with either drug...
October 15, 2015: Journal of the Neurological Sciences
Han Gil Seo, Nam-Jong Paik, Shi-Uk Lee, Byung-Mo Oh, Min Ho Chun, Bum Sun Kwon, Moon Suk Bang
BACKGROUND: Botulinum toxin type A is widely used for treating spasticity. Neuronox (Neu-BoNT/A), a newly manufactured botulinum toxin a, has not yet been investigated for its efficacy and safety in the treatment of post-stroke upper limb spasticity. OBJECTIVE: We evaluated the efficacy and safety of Neuronox (Neu-BoNT/A) compared with BOTOX (onabotulinum toxin A) for treating post-stroke upper limb spasticity. METHODS: In total, 196 stroke patients with moderate to severe upper limb spasticity were randomly assigned to either Neuronox or BOTOX intervention...
2015: PloS One
E V Kostenko, L V Petrova
OBJECTIVE: To examine the efficacy of onabotulinumtoxin A (Botox) in the complex rehabilitation of patients with post-stroke spasticity of the leg in the early rehabilitation period of stroke. MATERIALS AND METHODS: The study group comprised 31 patients in the early recovery period after stroke with the presence of equino-varus deformity of the foot with spasticity grade 3 or more (MAS). All patients received injections of onabotulinumtoxin A (Botox) in a total dose 400 ED as part of a comprehensive rehabilitation program...
2014: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Anthony B Ward, Jörg Wissel, Jörgen Borg, Per Ertzgaard, Christoph Herrmann, Jai Kulkarni, Kristina Lindgren, Iris Reuter, Mohamed Sakel, Patrik Säterö, Satyendra Sharma, Theodore Wein, Nicola Wright, Antony Fulford-Smith
OBJECTIVE: Evaluate changes in active and passive function with onabotulinumtoxinA + standard of care within goal-oriented rehabilitation programmes in adults with focal post-stroke spasticity. METHODS: Prospective, 24-week double-blind study with an open-label extension. Subjects were randomized to onabotulinumtoxinA + standard of care or placebo + standard of care, at baseline and at 12 weeks, if judged appropriate, with follow-up to 52 weeks. The primary endpoint was the number of patients achieving their principal active functional goal at 24 weeks (or 10 weeks after an optional second injection)...
June 2014: Journal of Rehabilitation Medicine
N Lampire, N Roche, P Carne, L Cheze, D Pradon
BACKGROUND: In hemiparetic patients, rectus femoris spasticity is one of the main causes of reduced knee flexion in swing phase, known as stiff knee gait. Botulinum toxin is often used to reduce rectus femoris spasticity and to increase knee flexion during swing phase. However, the mechanisms behind these improvements remain poorly understood. The aim of this study was (1) to quantify maximal rectus femoris length and lengthening velocity during gait in ten adult hemiparetic subjects with rectus femoris spasticity and stiff knee gait and to compare these parameters with those of ten healthy subjects and (2) to study the effect of botulinum toxin injection in the rectus femoris muscle on the same parameters...
February 2013: Clinical Biomechanics
Y Dionyssiotis, D Kiourtidis, A Karvouni, A Kaliontzoglou, I Kliafas
PURPOSE: The aim of this study was to investigate whether the consequences of neurologic lesions are underestimated when the Barthel Index (BI) is used to assess the clinical outcome of botulinum toxin injection. PATIENTS AND METHODS: The records for all in- and outpatients with various neurologic lesions (stroke, multiple sclerosis, spinal cord injury, traumatic brain injury, and so forth) who had been referred to the authors' departments and who had received botulinum toxin type A (Botox(®)) for spasticity within a 4-year period (2008-2011) were examined retrospectively...
2012: Therapeutics and Clinical Risk Management
Christina M Marciniak, Richard L Harvey, Christine M Gagnon, Sylvia A Duraski, Florence A Denby, Stacy McCarty, Lori A Bravi, Katie M Polo, Katie M Fierstein
OBJECTIVE: The aim of this study was to assess the efficacy of botulinum toxin type A injections in reducing pain, impairment, and disability in patients who have had a stroke with shoulder pain and spasticity. DESIGN: In this prospective randomized, double-blind, placebo-controlled trial, adults (n = 37) with post-stroke shoulder spasticity were screened for preinjection spasticity, rated 3 or 4 on the Modified Ashworth Scale for the shoulder adductors/internal rotators and shoulder pain...
December 2012: American Journal of Physical Medicine & Rehabilitation
Jong-Hyun Seo, Don-Kyu Kim, Si Hyun Kang, Kyung-Mook Seo, Ju Won Seok
A 62-year-old female patient diagnosed with left brain stem stroke 2 months ago was admitted to our clinic for rehabilitation. She had no generalized spasticity on both extremities, but could open her mouth only approximately 2 mm between her upper and lower teeth due to severe trismus. On needle electromyography, the left masseter muscle showed paradoxically increased muscle activity during mouth opening. We injected 50 units of type A botulinum toxin (Botox®) into the left masseter muscle, and 20 units into the left temporalis muscle with guidance of ultrasonography...
February 2012: Annals of Rehabilitation Medicine
John Walter Dunne, Jean-Michel Gracies, Michael Hayes, Brian Zeman, Barbara Jennifer Singer
OBJECTIVE: To examine the safety and efficacy of onabotulinumtoxinA (Botox) for plantarflexor overactivity following stroke. DESIGN: Double-blind randomized controlled trial, open-label extension phase. SETTING: Neurology rehabilitation facilities. SUBJECTS: Eighty-five subjects with lower limb hypertonia received 200 U (n = 28) or 300 U (n = 28) of onabotulinumtoxinA or saline (n = 29) injection. PRIMARY MEASURES: Plantarflexor Ashworth scores at 12 weeks post injection and adverse events...
September 2012: Clinical Rehabilitation
Matthew L Iorio, Derek L Masden, James P Higgins
OBJECTIVES: Botulinum toxin A has conventionally been used in the upper extremity to treat spasticity resulting from stroke, paraplegia, and dystonia. Recently, it has been used to relieve symptoms of vasospasm in Raynaud's phenomenon. This review summarizes the current literature on botulinum toxin A in the treatment of Raynaud's phenomenon and examines the proposed mechanisms of action, suggested techniques of administration, and clinical efficacy. METHODS: An Ovid MEDLINE search from 1950 to September 2010 was performed to identify any reports on the use of Botulinum toxin in the treatment of Raynaud's disease or associated vasoconstrictive disorders...
February 2012: Seminars in Arthritis and Rheumatism
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"